To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in
patients with B-cell non-Hodgkin's lymphoma
This is an open, single-arm, single-dose, dose-escalation clinical trial designed to evaluate
the safety and the preliminary efficacy of CB CAR-NK019 cells in vivo. 9-18 patients are
planned to be enrolled in the dose-escalation trial (2.5×10^8 cells/kg, 5×10^8 cells/kg,
1×10^9 cells/kg) . The primary endpoints are DLT, MTD, and the second endpionts are the
overall response rates (CR and PR), overall survival, and progression-free survival. Based on
the results in the dose-escalation trial, the recommended dose will be determined. Another 30
patients will be enrolled to estimate the safety and efficacy of CB CAR-NK019 under the best
B-cell Non Hodgkin Lymphoma
Clinical Study Identifier
Second Affiliated Hospital, School of Medicine, Zhejiang University
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.